In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $6.11 up 0.83% from its previous closing price of $6.06. In other words, the price has increased by $0.83 from its previous closing price. On the day, 3.83 million shares were traded. RXRX stock price reached its highest trading level at $6.34 during the session, while it also had its lowest trading level at $6.07.
Ratios:
For a deeper understanding of Recursion Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.07 and its Current Ratio is at 6.07. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 02 ’24 when Gibson Christopher sold 20,000 shares for $6.16 per share. The transaction valued at 123,200 led to the insider holds 762,656 shares of the business.
Gibson Christopher sold 20,000 shares of RXRX for $121,600 on Oct 03 ’24. The Chief Executive Officer now owns 762,656 shares after completing the transaction at $6.08 per share. On Oct 01 ’24, another insider, Borgeson Blake, who serves as the Director of the company, sold 11,447 shares for $6.22 each. As a result, the insider received 71,150 and left with 7,098,428 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 1724474368 and an Enterprise Value of 1332251136. For the stock, the TTM Price-to-Sale (P/S) ratio is 35.45 while its Price-to-Book (P/B) ratio in mrq is 2.94. Its current Enterprise Value per Revenue stands at 26.841 whereas that against EBITDA is -3.651.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $4.97. The 50-Day Moving Average of the stock is -11.34%, while the 200-Day Moving Average is calculated to be -32.00%.
Shares Statistics:
For the past three months, RXRX has traded an average of 5.09M shares per day and 4536840 over the past ten days. A total of 226.26M shares are outstanding, with a floating share count of 222.94M. Insiders hold about 22.57% of the company’s shares, while institutions hold 75.73% stake in the company. Shares short for RXRX as of 1726185600 were 59162424 with a Short Ratio of 11.62, compared to 1723680000 on 54147202. Therefore, it implies a Short% of Shares Outstanding of 59162424 and a Short% of Float of 29.220000000000002.
